BioSyent Releases 2007 Financial Results

MISSISSAUGA, ONTARIO (TSX VENTURE: RX) today released a summary of its 2007 financial results. For the twelve months ending December 31, 2007, sales decreased from $1,514,491 in 2006 to $1,104,325 in 2007. In 2006 total sales registered a high due to the confluence of favourable climatic and market conditions. 2007 sales reflect a higher plateau as compared to years prior to 2006. Sales for FeraMAX(TM) were modest in 2007 as it was not yet listed on various formularies, restricting its reimbursement.

Gross Margins increased to 69.0% in 2007, from 67.8% in the year ago period primarily because of margin improvement efforts and the lower cost of USD input costs.

The company incurred a loss of ($125,991) in 2007 compared to a profit of $383,145 in 2006. This loss is predominantly due to selling and marketing expenses to promote FeraMAX(TM) which was first shipped in April 2007 and lower sales of Protect-It� in 2007 as compared to 2006.

Total positive cash flow for 2007 was $27,566 versus cash generation of $214,241 in 2006. Total net working capital decreased from $1,201,720 on December 31, 2006 to $1,097,491 on December 31, 2007. Cash and cash equivalents increased from $1,050,206 in 2006 to $1,077,772.

Full details of 2007 results including December 31, 2006 Financial Statements and Management's Discussion & Analysis will be posted on sedar.com on April 2, 2008.

The company has licensed a new pharmaceutical product which will be launched in quarter two, 2008.

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

Contacts: BioSyent Inc. Rene C. Goehrum President and CEO (905) 206-0013 (905) 206-1413 (FAX) Email: rgoehrum@biosyent.com Website: www.biosyent.com

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024